LADRX CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.13 USD | -18.70% |
|
-23.38% | +63.85% |
| 04/06 | LadRx Corporation and ImmunityBio, Inc. Mutually Agree to Terminate Aldoxorubicin License | CI |
| 15/05 | LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 10.55L | - | - | - | - | - | |
| 5.11TCr | - | |||||
| 3.89TCr | ||||||
| 3.88TCr | ||||||
| 2.67TCr | ||||||
| 2.63TCr |
- Stock Market
- Equities
- LADX Stock
- Charts LadRx Corporation
- Sector Chart
